oalib

OALib Journal期刊

ISSN: 2333-9721

费用：99美元

投稿

时间不限

( 2026 )

( 2025 )

( 2024 )

( 2023 )

自定义范围…

匹配条件： “lung hemosiderosis” ，找到相关结果约1000条。
列表显示的所有文章，均可免费获取
第1页/共1000条
每页显示 条
Pulmón del soldador de arco
Molinari,Luciana; álvarez,Clarisa; Semeniuk,Guillermo B.;
Medicina (Buenos Aires) , 2010,
Abstract: pneumoconiosis of electric arc welder or siderotic pneumoconiosis was described by doig and mclaughlin in 1936 as a lung disease caused by chronic inhalation of iron fumes in electric arc welders. we present a case report of electric arc welder siderosis associated with high levels of ferritin, without findings of iron deposit in any other organ.
Idiopathic Pulmonary Hemosiderosis
Nur Dilek Bakan,Dilek Kanmaz,Gulcihan Ozkan,Muhammet Tekesin
Turk Toraks Dergisi , 2008,
Abstract: Idiopathic pulmonary hemosiderosis (IPH) is a rare cause of alveolar hemorrhage, characterized by recurrent episodes of alveolar hemorrhage, hemoptysis and secondary iron-deficiency anemia which occurs primarily in childhood. The pathogenesis is not known. A diagnosis of IPH can be made only when other causes of diffuse alveolar hemorrhage have been reliably excluded. A 15 year-old boy with recurrent cough, bloody sputum, dyspnea and chronic fatigue was hospitalized. Chest radiograph demonstrated bilateral alveolar infiltrates. HRCT revealed areas of ground glass opacities. Transbronchial lung biopsies showed alveolar hemosiderosis and the bronchoalveolar lavage fluid was rich in hemosiderin-laden macrophages. Serologic markers; ANA, anti-ds-DNA, RF, c-ANCA, p-ANCA, and anti-BM were negative. No evidence of other organ involvement was found. The patient was diagnosed as IPH and corticosteroid therapy was started.
Pulmón del soldador de arco Arc welder's lung
Luciana Molinari,Clarisa álvarez,Guillermo B. Semeniuk
Medicina (Buenos Aires) , 2010,
Abstract: La siderosis del soldador o neumoconiosis siderótica fue descripta por Doig y McLaughlin en 1936 como una enfermedad pulmonar causada por la inhalación crónica de polvo de hierro en soldadores de arco eléctrico. Presentamos un caso de siderosis del soldador asociada a aumento de los niveles de ferritina, sin hallazgo de depósito de hierro en otros órganos y sin causas evidentes de hemosiderosis secundaria. Pneumoconiosis of electric arc welder or siderotic pneumoconiosis was described by Doig and McLaughlin in 1936 as a lung disease caused by chronic inhalation of iron fumes in electric arc welders. We present a case report of electric arc welder siderosis associated with high levels of ferritin, without findings of iron deposit in any other organ.
Idiopathic pulmonary hemosiderosis: Alveoli are an answer to anemia
Bhatia S,Tullu M,Vaideeswar P,Lahiri K
Journal of Postgraduate Medicine , 2011,
Abstract: Idiopathic pulmonary hemosiderosis (IPH) is a rare disorder (triad of iron-deficiency anemia, hemoptysis, and alveolar infiltrates). A 3-year-old male presented with mild fever, breathlessness, dry cough, and bluish nail discoloration for 8 days. He had required five blood transfusions in the past 1 year (last transfusion was given 4 months ago). He had a respiratory rate of 58/min with respiratory distress, cyanosis, and grade III clubbing. Respiratory system examination was normal. Several previous reports of hemoglobin were as low as 3.6 g/dl with hypochromic and microcytic anemia. There were transient increases in the hemoglobin and normalization of red cell morphology with blood transfusions. Serum iron, G6PD enzyme assay, hemoglobin electrophoresis, the sickling test, Coomb′s test, stool and urine analysis, and a Meckel′s scan were normal. HIV antibody and dsDNA were negative. The chest radiograph revealed symmetrical patchy infiltrates sparing lung apices (confirmed on high-resolution computed tomography). Lung biopsy diagnosed pulmonary hemosiderosis (interstitial lung disease with hemosiderin-laden macrophages scattered in the alveoli and areas of fibrosis in the alveolar septa). The patient showed marked clinical improvement in 10 days of therapy with prednisolone. IPH should be listed in the differential diagnosis of a child presenting with unexplained hypochromic, microcytic anemia and respiratory symptoms.
Hemosiderosis pulmonar en una lactante Lung hemosiderosis in an infant
Zoila María Dilú Sorzano,Susana Cunill Romero,Caridad María Tamayo Reus,Melba Puzo Hansen
MEDISAN , 2013,
Abstract: Se presenta el caso clínico de una lactante de 11 meses de edad con hemosiderosis pulmonar, quien fue ingresada en el Hospital Infantil Sur de Santiago de Cuba por presentar manifestaciones respiratorias recurrentes desde los 5 meses, que coincidió con la supresión de la lactancia materna e inicio de la alimentación con leche de vaca, además de anemia microcítica e hipocrómica, infiltrado radiográfico característico, así como siderófagos en el contenido gástrico, síntomas que se correspondían con el síndrome de Heiner. El diagnóstico precoz y el tratamiento oportuno garantizaron la evolución favorable de la paciente. The case report of an 11 months female infant with lung hemosiderosis is presented. She was admitted to the Southern Hospital from Santiago de Cuba due to recurrent breathing manifestations since 5 months of age, which coincided with the discontinuation of breastfeeding and the beginning of feeding with cow milk, besides hypochromic microcytic anemia, characteristic radiographic infiltrate, as well as siderophages in the gastric content, symptoms which were in correspondence with Heiner syndrome. The early diagnosis and the opportune treatment guaranteed the favorable clinical course of the patient.
Hemosiderosis pulmonar idiopática
JULIO ESPINOZA,ERICH SIMPFENDORFER,JULIO HASBUN
Revista chilena de pediatría , 1958,
Abstract:
Hemosiderosis pulmonar idiopática
J SCHWARZENBERG,AMANDA FRITIS,RAMON FIGUEROA,A REID
Revista chilena de pediatría , 1958,
Abstract:
Pulmonary hemosiderosis in children with Down syndrome: a national experience
Aimé Ravel,Annick Clement,Antoine Deschildre,Aude Forgeron,Aurelia Alimi,Caroline Perisson,Caroline Thumerelle,Fran？oise Troussier,Guillaume Thouvenin,Harriet Corvol,Isabelle Gibertini,Jacques de Blic,Jessica Taytard,Jocelyne Derelle,Marc Lubrano Lavadera,Marie-Catherine Renoux,Michael Fayon,Nadia Nathan,Philippe Reix,Pierrick Cros,Ralph Epaud,Rola Abou Taam,Sophie Leyronnas,Sylvie Roullaud,Véronique Houdouin,for the French RespiRare？ group
- , 2018, DOI: 10.1186/s13023-018-0806-6
Abstract: The online version of this article (10.1186/s13023-018-0806-6) contains supplementary material, which is available to authorized users
IDIOPATHIC PULMONARY HEMOSIDEROSIS- A CASE REPORT
Gülay ？iler Erda？,Ay？a Vitrinel,Gül Ye？iltepe Mutlu,Yasemin Ak？n
Marmara Medical Journal , 2006,
Abstract: We report a case of idiopathic pulmonary hemosiderosis (IPH) in a 12 year old boy who presented with anemia without any pulmonary symptom. He had been investigated at a number of hospitals and had received multiple blood transfusions for iron deficiency anemia. At his first admission he was misdiagnosed as gastrointestinal bleeding because of hematemesis and occult blood in feces. Six months later, history of coughing blood guided us the probability of pulmonary hemosiderosis. The diagnosis of IPH was made after a biopsy of lung showed numbers of hemosiderosin-filled macrophages in the alveoli.
Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
Heslet L, Nielsen JD, Nepper-Christensen S
Biologics: Targets and Therapy , 2012, DOI: http://dx.doi.org/10.2147/BTT.S25507
Abstract: cal pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm Review (3200) Total Article Views Authors: Heslet L, Nielsen JD, Nepper-Christensen S Published Date March 2012 Volume 2012:6 Pages 37 - 46 DOI: http://dx.doi.org/10.2147/BTT.S25507 Received: 25 August 2011 Accepted: 16 December 2011 Published: 06 March 2012 Lars Heslet1, J rn Dalsgaard Nielsen2, Steen Nepper-Christensen3 1Serendex ApS, Parkovsvej 20, Gentofte, DK 2820 Denmark; 2Department of Hematology, University Hospital of Copenhagen, Rigshospitalet, Denmark; 3Department of Otolaryngology/Head and Neck Surgery, University Hospital of Copenhagen, Rigshospitalet, Denmark Background: Diffuse alveolar hemorrhage (DAH) is a clinical syndrome with typical symptoms dyspnea and hemoptysis. DAH is a complication of specific diseases, in some cases with acute catastrophic hemoptysis, while other patients present low grade alveolar bleeding with a need of chronic transfusion as in pulmonary hemosiderosis. Methods: Current literature in the PubMed database and other sources was reviewed in order to evaluate the current treatment recommendations, efficacy of this treatment, and finally the risk of complications after off-label use of rFVIIa in respect to DAH. Objectives: (i) To elucidate the clinical aspects of alveolar hemorrhage, (ii) to develop a simple diagnostic algorithm in order to separate DAH from other important pulmonary diseases with similar clinical picture and comparably high mortality. Such an algorithm has important therapeutic consequences because these diseases: acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and bronchiolitis obliterans organizing pneumonia (BOOP) have different therapies, (iii) to evaluate and discuss whether local pulmonary administration may improve outcome and reduce mortality in DAH, and (iv) to suggest a treatment schedule. Results: Hitherto the diagnosis and treatment of DAH has been based on anecdotal reports. The treatment has relied on different unspecific treatment modalities based on a mixture of treatment of the underlying disease and treatment without evidence targeted to stop the alveolar bleeding. However, recently a number of publications have advocated the use of intrapulmonary rFVIIa. Even in severe bleeding DAH has been shown to respond promptly without thromboembolic complication when FVIIa was administered locally via the air side, because the FVIIa does not penetrate the alveolo-capillary membrane to the blood-side. The incidence of DAH (in the US and Europe is 100,000–150,000, and 50,000 patients annually are at risk of developing DAH following hematopoietic stem cell transplant (HSCT) and autoimmune diseases. Finally 50,000–100,000 patients may be falsely categorized as having acute respiratory distress syndrome/acute lung injury (ARDS/ALI) because DAH and ARDS cannot be separated clinically. A new treatment paradigm of DAH is proposed as no other i
第1页/共1000条
每页显示 条


Home
Copyright © 2008-2020 Open Access Library. All rights reserved.